Department of Radiology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Republic of Korea.
Department of Radiology, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea.
Eur Radiol. 2018 Aug;28(8):3176-3184. doi: 10.1007/s00330-017-5293-y. Epub 2018 Apr 6.
To evaluate the changes in mammographic density after tamoxifen discontinuation in premenopausal women with oestrogen receptor-positive breast cancers and the underlying factors METHODS: A total of 213 consecutive premenopausal women with breast cancer who received tamoxifen treatment after curative surgery and underwent three mammograms (baseline, after tamoxifen treatment, after tamoxifen discontinuation) were included. Changes in mammographic density after tamoxifen discontinuation were assessed qualitatively (decrease, no change, or increase) by two readers and measured quantitatively by semi-automated software. The association between % density change and clinicopathological factors was evaluated using univariate and multivariate regression analyses.
After tamoxifen discontinuation, a mammographic density increase was observed in 31.9% (68/213, reader 1) to 22.1% (47/213, reader 2) by qualitative assessment, with a mean density increase of 1.8% by quantitative assessment compared to density before tamoxifen discontinuation. In multivariate analysis, younger age (≤ 39 years) and greater % density decline after tamoxifen treatment (≥ 17.0%) were independent factors associated with density change after tamoxifen discontinuation (p < .001 and p = .003, respectively).
Tamoxifen discontinuation was associated with mammographic density change with a mean density increase of 1.8%, which was associated with younger age and greater density change after tamoxifen treatment.
• Increased mammographic density after tamoxifen discontinuation can occur in premenopausal women. • Mean density increase after tamoxifen discontinuation was 1.8%. • Density increase is associated with age and density decrease after tamoxifen.
评估绝经前雌激素受体阳性乳腺癌患者停用他莫昔芬后乳腺密度的变化及其潜在因素。
共纳入 213 例接受根治性手术后接受他莫昔芬治疗并接受 3 次乳腺 X 线摄影（基线、他莫昔芬治疗后、他莫昔芬停药后）的连续绝经前乳腺癌患者。由 2 位读者对他莫昔芬停药后乳腺密度的变化进行定性评估（减少、无变化或增加），并通过半自动软件进行定量测量。使用单变量和多变量回归分析评估密度变化百分比与临床病理因素之间的关系。
在定性评估中，他莫昔芬停药后，31.9%（213 例患者中的 68 例，读者 1）至 22.1%（213 例患者中的 47 例，读者 2）观察到乳腺密度增加，与他莫昔芬停药前相比，定量评估的平均密度增加 1.8%。多变量分析显示，年龄较小（≤39 岁）和他莫昔芬治疗后密度下降百分比较大（≥17.0%）是与他莫昔芬停药后密度变化相关的独立因素（p<0.001 和 p=0.003）。
他莫昔芬停药与乳腺密度变化相关，平均密度增加 1.8%，与年龄较小和他莫昔芬治疗后密度下降更大相关。
绝经前妇女停用他莫昔芬后乳腺密度可能增加。
他莫昔芬停药后密度平均增加 1.8%。
密度增加与年龄和他莫昔芬停药后密度下降有关。
